Tenax Therapeutics Inc Total Assets
Tenax Therapeutics Inc total assets. Based on the latest financial reports, Tenax Therapeutics Inc (TENX) holds total assets worth $121.66 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Tenax Therapeutics Inc (TENX) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Tenax Therapeutics Inc (1995–2025)
Total assets of Tenax Therapeutics Inc from 1995 to 2025. This chart illustrates how Tenax Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See Tenax Therapeutics Inc (TENX) share price today for real-time trading data and today's change.
Tenax Therapeutics Inc - Asset Composition Analysis
Tenax Therapeutics Inc Total Assets Breakdown (December 2025)
Tenax Therapeutics Inc total assets breakdown as of December 2025. Tenax Therapeutics Inc's total assets of $121.66 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 93.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1995–2025)
This chart illustrates how Tenax Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore TENX working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tenax Therapeutics Inc's current assets represent 100.0% of total assets in 2025, an increase from 26.9% in 1995.
- Cash Position: Cash and equivalents constituted 93.6% of total assets in 2025, up from 19.4% in 1995.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 21.0% in 1995.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Tenax Therapeutics Inc Competitors by Total Assets
Key competitors of Tenax Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Tenax Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 15.07 | 41.89 | 5.87 |
| Quick Ratio | 15.07 | 41.89 | 5.87 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $113.59 Million | $103.33 Million | $7.12 Million |
Tenax Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Tenax Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.63 |
| Latest Market Cap to Assets Ratio | 0.65 |
| Asset Growth Rate (YoY) | 7.8% |
| Total Assets | $104.23 Million |
| Market Capitalization | $67.74 Million USD |
Valuation Analysis
Below Book Valuation: The market values Tenax Therapeutics Inc's assets below their book value (0.65x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Tenax Therapeutics Inc's assets grew by 7.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Tenax Therapeutics Inc (1995–2025)
The table below shows the annual total assets of Tenax Therapeutics Inc from 1995 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $104.23 Million | +7.80% |
| 2024-12-31 | $96.69 Million | +727.46% |
| 2023-12-31 | $11.68 Million | +243.19% |
| 2022-12-31 | $3.40 Million | -43.18% |
| 2021-12-31 | $5.99 Million | -12.76% |
| 2020-12-31 | $6.87 Million | +7.91% |
| 2019-12-31 | $6.37 Million | -52.27% |
| 2018-12-31 | $13.34 Million | +34.85% |
| 2017-12-31 | $9.89 Million | -57.62% |
| 2016-12-31 | $23.34 Million | -68.02% |
| 2015-12-31 | $72.99 Million | -21.88% |
| 2014-12-31 | $93.43 Million | 0.00% |
| 2013-12-31 | $93.43 Million | +175.31% |
| 2012-12-31 | $33.94 Million | +476.14% |
| 2011-12-31 | $5.89 Million | +66.90% |
| 2010-12-31 | $3.53 Million | -29.82% |
| 2009-12-31 | $5.03 Million | -40.10% |
| 2008-12-31 | $8.39 Million | +319.42% |
| 2007-12-31 | $2.00 Million | +227.70% |
| 2006-12-31 | $610.79K | -51.61% |
| 2005-12-31 | $1.26 Million | -30.24% |
| 2004-12-31 | $1.81 Million | +21.77% |
| 2003-12-31 | $1.49 Million | +12.80% |
| 2002-12-31 | $1.32 Million | -65.26% |
| 2001-12-31 | $3.79 Million | -38.83% |
| 2000-12-31 | $6.20 Million | +1139.93% |
| 1999-12-31 | $500.00K | -49.29% |
| 1998-12-31 | $985.91K | +209.88% |
| 1997-12-31 | $318.16K | -19.24% |
| 1996-12-31 | $393.94K | 0.00% |
| 1995-12-31 | $393.94K | -- |
About Tenax Therapeutics Inc
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imat… Read more